Jump to content

IDNNA

From Wikipedia, the free encyclopedia
IDNNA
Names
Preferred IUPAC name
1-(4-Iodo-2,5-dimethoxyphenyl)-N,N-dimethylpropan-2-amine
Other names
2,5-Dimethoxy-4-iodo-N,N-dimethylamphetamine
2,5-Dimethoxy-4-iodo-1-ethyl-(α-methyl)amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C13H20INO2/c1-9(15(2)3)6-10-7-13(17-5)11(14)8-12(10)16-4/h7-9H,6H2,1-5H3 checkY
    Key: XBCUSBRGRALQID-UHFFFAOYSA-N checkY
  • InChI=1/C13H20INO2/c1-9(15(2)3)6-10-7-13(17-5)11(14)8-12(10)16-4/h7-9H,6H2,1-5H3
    Key: XBCUSBRGRALQID-UHFFFAOYAY
  • Ic1cc(OC)c(cc1OC)CC(N(C)C)C
Properties
C13H20NO2I
Molar mass 349.211 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

IDNNA (2,5-dimethoxy-4-iodo-N,N-dimethylamphetamine) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N,N-dimethyl analog of DOI. IDNNA was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 2.6 mg, and the duration unknown.[1] IDNNA produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of IDNNA.

Legality

[edit]

United Kingdom

[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

[edit]

References

[edit]
  1. ^ IDNNA Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.